By Doc Louallen
Scribe Therapeutics filed for an initial public offering.
The biotechnology company didn't say how many shares it would offer or at what price, and said the underwriters have a 30-day option to buy more shares.
Scribe said it has applied to list on Nasdaq under the symbol SCTX.
The company also said it will use the money, along with existing cash, to move its lead program forward (STX-1150), advance other programs in development, keep building its CRISPR platforms, and cover general corporate needs.
For the quarter ended March 31, 2026, Scribe reported a net loss of $17.3 million, compared with a net loss of $3.4 million a year earlier. Revenue fell to $2.2 million from $17.1 million year over year.
Write to Doc Louallen at Doc.Louallen@wsj.com